Streptococcus pneumoniae type 15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen
Streptococcus pneumoniae type 15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of Streptococcus pneumoniae serotype 15B individually conjugated to... The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.
- First approval
- United States, 2021
- Brand names
Resolves to
What you can answer from here — as of April 02, 2025
Which companies are running trials of Streptococcus pneumoniae type 15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account